Pinpoint Radiotherapy Procedure Shown Effective for Breast Cancer

The study, conducted by investigators from the European Institute of Oncology (IEO; Milan, Italy), was published in the February 28, 2008, issue of the journal ecancermedicalscience. The investigators examined the use of electron intraoperative therapy (ELIOT), which reduces the radiotherapy course from six weeks to one single session during surgery.

The traditional treatment for early breast cancer is breast-conserving surgery (BCS) followed by a five to seven week course of radiotherapy. However, many women still undergo mastectomies because they do not have easy access to postoperative radiotherapy centers. As 85% of local relapses after BCS occur near the initial site of disease, there has been an increased interest in using partial breast irradiation (PBI) directed to the tissue immediately surrounding the site of tumor removal.

Investigators have evaluated the use of ELIOT alone for early-stage breast cancer since 1999. This technique uses radiotherapy machines kept or easily moved in the operating room. After removal of the tumor, a high accuracy, high-dose radiation pulse is delivered to the breast tissue surrounding the site. Since it was first piloted by the IEO in 1999, ELIOT has been given to 1,246 patients, with an overall survival rate at five years of 96.5%. Only 24 out of the 1,246 cases (1.9%) saw a breast-cancer related event after this period.

Apart from this success, the system has several other advantages: Cosmetic damage is greatly limited and post-op plastic surgery is easily conducted. The flexible nature of the radiotherapy machine and its presence during surgery means that additional doses of radiotherapy can be given if needed for specific reasons. Furthermore, the complete protection against radiation provided by the combination of pinpoint doses and protective metal disk means that side effects from unwanted radiation are abolished.

The main advantage, however, is for those patients living in areas remote from radiotherapy centers, who would otherwise have to travel everyday for six weeks, and often decide on complete breast removal to avoid the huge stress of such an undertaking.

The investigators stated that their results, "confirmed the positive impact of ELIOT on patient quality of life: ELIOT is feasible and well accepted. We are waiting for the long-term results on local control from the ongoing randomized trial in progress at our institute to decide whether to adopt the technique in daily standard practice. However, as the data from the present large series are reassuring [97% of local control and 98.8% survival at five years], we believe that, at least for women living far from radiotherapy centers and with minimal risk of local recurrence [age > 50 and primary carcinoma < 1.5 cm.], the ELIOT treatment might be considered an option, provided that the patient consents to the proposal.”

Prof. Gordon McVie, of the European Institute of Oncology, added, "this is the largest experience in the world of sequential patients treated in a phase II trial with intra-operative radiotherapy. Its unprecedented size and positive results gives great hope for both this technique and breast cancer patients worldwide.”


Related Links:
European Institute of Oncology